NewAmsterdam Pharma Company N.V. $NAMS Shares Bought by Aberdeen Group plc

Key Points

• Aberdeen Group plc significantly increased its stake in NewAmsterdam Pharma Company N.V. by 95.0%, owning a total of 735,032 shares valued at approximately $13.3 million as of its latest SEC filing.
• Despite recent gains in institutional ownership, several analysts maintain cautious ratings on the stock, with Weiss Ratings reaffirming a "sell (d-)" and Royal Bank of Canada raising its price target to $39.00 while giving an "outperform" rating.
• Insider transactions showed significant selling activity, with notable insiders selling a combined total of 200,000 shares, reflecting a substantial reduction in their positions.

Aberdeen Group plc raised its stake in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 95.0% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 735,032 shares of the company's stock after acquiring an additional 358,169 shares during the period. Aberdeen Group plc owned 0.65% of NewAmsterdam Pharma worth $13,311,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Frazier Life Sciences Management L.P. boosted its stake in NewAmsterdam Pharma by 1.3% in the first quarter. Frazier Life Sciences Management L.P. now owns 16,116,418 shares of the company's stock valued at $329,903,000 after acquiring an additional 200,000 shares during the period. RA Capital Management L.P. boosted its stake in NewAmsterdam Pharma by 14.6% in the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock valued at $207,544,000 after acquiring an additional 1,293,938 shares during the period. Wellington Management Group LLP raised its holdings in shares of NewAmsterdam Pharma by 53.0% during the first quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company's stock valued at $72,504,000 after buying an additional 1,226,852 shares during the last quarter. Woodline Partners LP raised its holdings in shares of NewAmsterdam Pharma by 0.5% during the first quarter. Woodline Partners LP now owns 2,442,397 shares of the company's stock valued at $49,996,000 after buying an additional 11,615 shares during the last quarter. Finally, Alliancebernstein L.P. raised its holdings in shares of NewAmsterdam Pharma by 20.7% during the first quarter. Alliancebernstein L.P. now owns 2,241,953 shares of the company's stock valued at $45,893,000 after buying an additional 383,888 shares during the last quarter. 89.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on NAMS shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of NewAmsterdam Pharma in a report on Wednesday, October 8th. Royal Bank Of Canada lifted their price target on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a report on Thursday, August 7th. Wells Fargo & Company started coverage on NewAmsterdam Pharma in a report on Monday, August 25th. They set an "overweight" rating and a $45.00 price target on the stock. Wall Street Zen raised NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. Finally, The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a report on Thursday, July 17th. They set a "neutral" rating and a $27.00 price target on the stock. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, NewAmsterdam Pharma presently has a consensus rating of "Moderate Buy" and an average price target of $42.00.

Insider Buying and Selling

In other NewAmsterdam Pharma news, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the company's stock in a transaction on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider owned 119,302 shares of the company's stock, valued at approximately $2,897,845.58. This represents a 29.53% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Louise Frederika Kooij sold 150,000 shares of the company's stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $25.83, for a total value of $3,874,500.00. Following the completion of the transaction, the chief accounting officer directly owned 15,000 shares in the company, valued at $387,450. This represents a 90.91% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have bought 2,391 shares of company stock valued at $58,424 and have sold 226,342 shares valued at $5,748,019. 20.84% of the stock is owned by corporate insiders.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $40.45 on Thursday. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $41.47. The stock has a market cap of $4.56 billion, a price-to-earnings ratio of -24.97 and a beta of 0.02. The stock's 50 day moving average price is $27.34 and its 200 day moving average price is $21.97.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last announced its earnings results on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative return on equity of 27.27% and a negative net margin of 259.07%.The firm had revenue of $19.15 million for the quarter, compared to analysts' expectations of $1.44 million. On average, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

Want to see what other hedge funds are holding NAMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.